Tacrolimus-accelerated renal interstitial injury in subtotal nephrectomized rats and its pharmacological modulation

Yuko Nakayama1, Sachiko Kamikawa2, Satohiro Masuda2

  • 1Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, Himeji, Hyōgo 670-8524, Japan.

Toxicology Letters
|April 30, 2026
PubMed

Insights

This study developed a rat model for tacrolimus-accelerated kidney injury in reduced renal reserve. Everolimus co-treatment partially mitigated tacrolimus-induced renal dysfunction and damage.

Area of Science:

  • Nephrology
  • Pharmacology
  • Experimental Pathology

Background:

  • Tacrolimus (a calcineurin inhibitor) causes chronic nephrotoxicity, especially with reduced renal reserve.
  • Existing experimental models for tacrolimus-accelerated renal injury are limited.
  • A need exists for efficient in vivo models to study this toxicity.

Purpose of the Study:

  • To establish and validate an in vivo model for tacrolimus-accelerated renal injury.
  • To assess the protective effects of everolimus in this model.

Main Methods:

  • Subtotal (5/6) nephrectomized rats were used to create reduced renal reserve.
  • Low-dose tacrolimus was administered for two weeks post-surgery.
  • Renal function (creatinine, albuminuria) and histology were evaluated.
  • Everolimus was co-administered to assess its modulatory effects.

Main Results:

  • Tacrolimus significantly worsened renal dysfunction and structural damage in nephrectomized rats.
  • Increased plasma creatinine, albuminuria, and interstitial fibrosis were observed.
  • Everolimus co-treatment partially attenuated these functional and histopathological changes.

Conclusions:

  • A novel in vivo model for tacrolimus-accelerated renal injury under reduced renal reserve was successfully established.
  • Everolimus demonstrated partial renoprotective effects in this experimental model.